Astarte Medical, a Yardley, Pennsylvania digital health startup focusing on infant microbiome health, has raised a $5 million Series A from a large stable of investors including Viking Global Investors, Lunsford Capital, OCA Ventures, Keiretsu Forum MidAtlantic, Keiretsu Capital Fund, Ben Franklin Technology Partners, Wing VC and Next Act Fund. This is the company’s first institutional round, but it has participated in at least three accelerators — MassChallenge HealthTech, Illumina Accelerator, and XLerate Health — and pitched at HIMSS and SxSW.

WHAT THEY DO

Astarte is building a suite of tools for the neonatal intensive care unit (NICU) called NICUtrition. The software suite will be built on a proprietary database of feeding protocols, microbial profiles and clinical information which will power predictive analytics that can advise care teams on protocols and treatment plans.

“We are thrilled to support Astarte Medical as they develop cutting-edge technology to solve some of the biggest problems for the smallest patients,” Bruce Lunsford, chairman and CEO of Lunsford Capital, said in a statement. “With its first solution, the company is poised to make a difference for not just the preterm babies, but also for clinical teams in NICUs where it will help streamline the workflow and increase efficiencies. Astarte Medical is addressing the needs of a large and underserved market, and we look forward to seeing the company positively impact the industry, lowering healthcare costs and improving health for generations to come.”

Read the full MobiHealthNews article here.